A Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirus

Simple item page
AuthorEnsieh Lotfalien
AuthorReza Ghasemien
AuthorMasoud Mardanien
AuthorAzam Fattahien
AuthorKamran Rezaeien
AuthorHossein Toreyhien
AuthorSara Abolghasemien
OrcidEnsieh Lotfali [0000-0001-6709-1320]en
OrcidReza Ghasemi [0000-0002-9704-9753]en
OrcidMasoud Mardani [0000-0001-6082-072X]en
OrcidAzam Fattahi [0000-0003-3613-4644]en
OrcidKamran Rezaei [0000-0002-0451-3175]en
OrcidHossein Toreyhi [0000-0002-4856-6674]en
OrcidSara Abolghasemi [0000-0001-7117-6079]en
Issued Date2020-06-30en
AbstractSince late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data concerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.en
DOIhttps://doi.org/10.5812/archcid.107788en
URIhttps://brieflands.com/journals/archcid/articles/107788en
KeywordCoronavirusen
KeywordCOVID-19en
KeywordSARS-CoV-2en
KeywordSevere Acute Respiratory Syndrome Coronavirus 2en
KeywordHematological Malignant Patientsen
PublisherBrieflandsen
TitleA Review on Hematologic Malignant Patients Infected with 2019 Novel Coronavirusen
TypeReview Articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
archcid-15-3-107788.pdf
Size:
145.65 KB
Format:
Adobe Portable Document Format
Description:
Article/s PDF
Download

Collections

Archives of Clinical Infectious Diseases